Guilin Pharmaceutical Group Co., Ltd.

HONG KONG, Nov. 9, 2022 /PRNewswire/ -- On 8 November 2022, we received good news from the 5th China International Import Expo (CIIE): the 1st In Shanghai, For the World has announced the recipients of the IP SHANGHAI Global Communications Corporate Case Best Practice Award. The organizing committee awarded Fosun International the IP SHANGHAI Global Communications Corporate Case Best Practice Award, in recognition of Fosun International's outstanding practices in global public health, including anti-malaria and anti-epidemic efforts. This is China's first large-scale global communications corporate case event themed on urban IP. The event was organized by IP SHANGHAI and the Global Communications Case Management Platform of Shanghai International Studies University and was supported by the Shanghai Daily Multinational Companies Club. As an enterprise rooted in Shanghai, China, Fosun has always been devoting itself to public health with its innovative products and global resources. Over the years, it has participated in anti-malarial campaigns in China and around the world, and has organized a series of public welfare activities with its global member companies to raise awareness and importance of malaria prevention and control around the world. Self-developed and Manufactured Artesuante for Injection to Build a Malaria-free World According to World Health Organization (WHO), in 2020, there were an estimated 241 million cases of malaria worldwide and 627,000 malaria-related deaths in the world. Among which, 95% of the cases and 96% of malaria-related deaths occurred in Africa, with about 80% being children under the age of five. In the 1970s, Chinese scientist Tu Youyou first developed a new technology to extract artemisinin from ether. Based on this technology, a series of new antimalarial drugs, including China No. X-01 artesunate, was developed, which innovatively advanced the fight against malaria. On 21 December 2005, artesunate tablet innovated by Fosun Pharma became the first pharmaceutical product prequalified by WHO (WHO-PQ), representing a breakthrough for the Chinese pharmaceutical industry. In 2011, Artesun®, artesunate for injection, which was self-developed and manufactured by Fosun Pharma, was recommended by the WHO as a first-line treatment of severe malaria. By the end of 2021, it has been used to treat over 48 million severe malaria patients worldwide. Fosun has been working unremittingly to support the global fight against malaria. In April 2021, Fosun Foundation responded actively to the "Zero Malaria Starts with Me" campaign initiated by the WHO and the "Roll Back Malaria Partnership". Slogans, "Zero Malaria Starts with Me" and "Together We Build a Malaria-free World", were displayed on the advertising screens of Fosun's landmark buildings, including the Bund Finance Center in Shanghai, 28 Liberty in New York, EN Hotel Kyoto and EN Hotel Hiroshima in Japan, Atlantis Sanya, the Bund Fosun Center in Wuhan. The English Premier League Wolverhampton Wanderers FC players made a video to call on everyone to take malaria prevention and control measures seriously and emphasize that malaria prevention and control is as important as taking good precautionary measures against COVID-19. Fosun Foundation and Fosun Pharma organized the "Draw a Malaria-free World" drawing competition at the Beacon International School in Ghana to educate children about malaria prevention and environmental protection. Fosun carried out a series of public welfare activities to call on the public to work together to fight against malaria. Using Chinese Antimalarial Drugs in Africa to Help More People In order to achieve the ultimate goal of building a malaria-free world, Fosuner, Cyrus Baidoo, has gone to the front line in Africa, where malaria is the most serious, and helped and cured many malaria patients with Chinese antimalarial drugs. Cyrus Baidoo is the Marketing Manager of Fosun Pharma Sub-Saharan Africa. He visits many local hospitals every day to promote Chinese antimalarial drugs to doctors and patients. Many years ago, Cyrus worked in a world-renowned pharmaceutical company before joining Fosun. "A lot of my friends did not understand why I left an American company for a Chinese company. They said the company is too new and barely has any products," recalls Cyrus. From being unfamiliar with and distrusting Chinese companies to now, where Fosun Pharma has become a global leader in malaria drugs and one of the most influential Chinese pharmaceutical brands in Africa, Cyrus witnessed the rapid development of Fosun Pharma in the field of antimalarial drugs. As of January 2022, Guilin Pharma, a subsidiary of Fosun Pharma, has a total of 30 antimalarial products prequalified by WHO (WHO-PQ), including 26 finished dosage forms and four APIs, making Fosun Pharma the leading antimalarial drug manufacturer with the most certifications. In August 2018, Fosun Pharma's SPAQ-CO® Disp (co-packed sulfadoxine-pyrimethamine dispersible tablets and amodiaquine dispersible tablets), which indicated for the prevention of malaria in children, was pre-qualified by WHO (WHO-PQ). By the end of 2021, around 175 million children in high malaria transmission African countries had benefited from the "Seasonal Malaria Chemoprevention Program", for which SPAQ-CO® Disp is used as the core drug to effectively reduce the morbidity of malaria in children under five years old in Africa. Guo Guangchang, Chairman of Fosun International, said, "As a partner in the fight against malaria for China and the world, Fosun consistently commits to providing more cutting-edge solutions such as innovative medicinal products and global resources for malaria management and control. We will join forces and resources, and work together with malaria scientists as well as healthcare professionals to continue to carry out malaria education projects for the public, so as to leverage people's awareness of malaria prevention. We will actively participate in public health improvement and make steady efforts to build a malaria-free world." In Shanghai, For the World. Thirty years after its establishment, Fosun will continue to uphold the original aspiration of "Self-improvement, Teamwork, Performance, and Contribution to Society", devote itself to global public health and public welfare undertakings, and provide innovative products and services to create happier lives for families worldwide. SOURCE Fosun

序号受理号药品名称申报单位批准文号签发日期1CXSS2101008国普特利单抗注射液乐普生物科技股份有限公司/2022年09月20日2CYHB2150810国注射用达托霉素浙江海正药业股份有限公司/2022年09月26日3CYHB2201479国壬苯醇醚栓国药集团工业有限公司/2022年09月26日4CYHB2201618国葡萄糖注射液北京远方通达医药技术有限公司/2022年09月26日5CYHB2201619国葡萄糖注射液北京远方通达医药技术有限公司/2022年09月26日6CYHB2201625国托伐普坦片桂林南药股份有限公司/2022年09月26日7CYZB2200754国舒肝健胃丸商丘市金马药业有限公司/2022年09月26日8CYZB2201031国小儿咽扁颗粒达嘉维康生物制药有限公司/2022年09月26日9CYZB2201033国板蓝根颗粒达嘉维康生物制药有限公司/2022年09月26日10CYZB2201034国板蓝根颗粒达嘉维康生物制药有限公司/2022年09月26日11CYZB2201035国肠康片达嘉维康生物制药有限公司/2022年09月26日12CYZB2201036国活力源口服液哈药集团中药二厂/2022年09月26日13CYZB2201037国双黄连糖浆哈药集团中药二厂/2022年09月26日14CYZB2201038国脑心舒口服液哈药集团中药二厂/2022年09月26日15CYZB2201039国妇良片达嘉维康生物制药有限公司/2022年09月26日16CYZB2201040国妇良片达嘉维康生物制药有限公司/2022年09月26日17CYZB2201041国肝泰颗粒达嘉维康生物制药有限公司/2022年09月26日18CYZB2201042国元胡止痛片兰州佛慈（瑞诺欣）药业股份有限公司/2022年09月26日19CYZB2201043国天麻片兰州佛慈（瑞诺欣）药业股份有限公司/2022年09月26日20CYZB2201044国五味子颗粒兰州佛慈（瑞诺欣）药业股份有限公司/2022年09月26日21CYZB2201048国七子补肾酒达嘉维康生物制药有限公司/2022年09月26日22CYZB2201049国补肾温阳酒达嘉维康生物制药有限公司/2022年09月26日23CYZB2201050国壮元补身酒达嘉维康生物制药有限公司/2022年09月26日24CYZB2201051国陈香露白露片达嘉维康生物制药有限公司/2022年09月26日25CYZB2201052国参苓白术丸安徽张恒春药业股份有限公司/2022年09月26日26CYZB2201053国培坤丸陕西棕泰药业有限公司/2022年09月26日27CYZB2201054国强肝丸陕西棕泰药业有限公司/2022年09月26日28JTH2200173盐酸甲氧氯普胺广东中润药物研发有限公司/2022年09月26日29JTH2200175雌二醇半水合物拜耳医药保健有限公司/2022年09月26日30JTH22001776α-羟基-戊酸雌二醇拜耳医药保健有限公司/2022年09月26日31JTH22001786-酮-戊酸雌二醇拜耳医药保健有限公司/2022年09月26日32JTH22001823,6,20-三酮拜耳医药保健有限公司/2022年09月26日

精彩内容日前，国家药监局官网显示，乐普恒久远药业的阿司匹林肠溶片以补充申请获批过评，成为该产品第2家过评企业。米内网数据显示，阿司匹林肠溶片在2021年中国三大终端6大市场销售规模超过35亿元，拜耳的市场份额最大。目前，有超过200家企业拥有生产批文。阿司匹林肠溶片对血小板聚集有抑制作用，可用于预防短暂脑缺血发作、心肌梗死、人工心脏瓣膜和静脉瘘或其他手术后血栓的形成。米内网数据显示，阿司匹林肠溶片在2021年中国三大终端6大市场（统计范围详见本文末）销售规模超过35亿元，拜耳的市场份额最大。目前，阿司匹林肠溶片有超过200家企业拥有生产批文，仅有2家企业过评。南京道群医药|南京白敬宇制药和桂林南药的一致性评价补充申请在审，重庆药友制药、烟台鲁银药业、浙江恒研医药|浙江赛默制药以仿制4类报产在审，获批后将视同过评。乐普此前过评产品情况来源：米内网MED2.0中国药品审评数据库在此之前，乐普已有12个产品过评，涵盖脑血管治疗用药、抗血栓形成药、糖尿病用药等多个治疗亚类。其中，盐酸倍他司汀片、缬沙坦氨氯地平片(Ⅰ)、磷酸西格列汀片均在今年获批过评。资料来源：米内网数据库、公司公告等注：米内网《中国三大终端6大市场竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦